The Janssen Pharmaceutical Companies of Johnson & Johnson discovered first-of-its-kind ERLEADA® (apalutamide) for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
The androgen receptor inhibitor ERLEADA® (apalutamide) is used to treat non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC).
ERLEADA® (apalutamide), is available for patients as the first-and-only next-generation androgen receptor inhibitor with once-daily tablet.
With two strengths available, the healthcare professionals consists of the flexibility to prescribe 240mg once-daily dose of ERLEADA® either in the form of one 240mg tablet or four 60mg tablets. The patients can prefer single-tablet option to reduce their total number of daily pills.
For patients having difficulty in swallowing tablets, ERLEADA® remains as the only single-tablet androgen receptor inhibitor (ARI) with alternate methods of administration. The 60 mg tablets are approved for dispersion in applesauce, while the 240 mg tablets are approved for orange juice, water or applesauce. The 240 mg tablet can also be delivered through a feeding tube.
